Status:
COMPLETED
Removal of Ligand-bound Iron During Intravenous (IV) Iron Administration in Hemodialysis (HD)
Lead Sponsor:
Soroka University Medical Center
Collaborating Sponsors:
Bnai Zion Medical Center
Rivka Ziv Medical Center
Conditions:
Hemodialysis Patients
Eligibility:
All Genders
18-88 years
Phase:
NA
Brief Summary
The study's hypothesis is that HD with large pore dialyzers remove to the dialysate iron which is bound to potentially dialyzable ligands, after it's release from intravenous iron compound administere...
Detailed Description
Most hemodialysis(HD) patients receive during HD intravenous iron compounds, which are composed of an iron core and a sugar polymer shell. A small percentage of iron from the iron compound is release...
Eligibility Criteria
Inclusion
- Chronic hemodialysis patients
Exclusion
- Acute disease (infection, thrombosis, ischemia, bleeding) Hepatitis B, Hepatitis C or HIV
- Intravenous iron administration or packed red cell transfusion in the last 3 weeks prior to the study
- Refusal to comply with limitations in fat containing food during HD with plasma sampling for AOPP evaluation
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00638300
Start Date
March 1 2008
End Date
July 1 2010
Last Update
July 13 2010
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
HD unit in Department of Nephrology in Soroka Universty Medical Center
Beersheba, Israel, 84101
2
HD unit in Bnai-zion Medical Center
Haifa, Israel
3
Rivka Ziv Medical center
Safed, Israel